plc, (NASDAQ: ICLR), a global provider of outsourced
development services to the pharmaceutical, biotechnology and medical
device industries, today announced the appointment of Dr. Hugh Brady as
a non-executive director.
Dr. Brady is President Emeritus of University College Dublin (UCD), one
of Europe's leading research-intensive universities, where he served as
President from 2004 until the end of 2013. During his tenure Dr. Brady
oversaw a significant expansion of UCD's science, engineering and
biomedical research capacity, including the development of the Conway
Institute for Biomedical Research, UCD Clinical Research Centre and the
Dublin Academic Medical Centre. In addition, he led a major growth in
UCD's international footprint, including the establishment of the
Beijing-Dublin International College and the UCD Shenzhen Health
Sciences Institute in China.
A nephrologist by training, Dr. Brady was Professor of Medicine and
Therapeutics at UCD before being appointed the university's President.
He returned to Ireland having built a successful career as a physician
and biomedical research scientist in the US, where he spent nine years
at Harvard University, including a period as Associate Professor of
Medicine. In parallel with his academic career at Harvard, he served as
Director of the Renal Division of the Brockton/West Roxbury VA Medical
Center and Consultant Physician at the Brigham and Women's Hospital,
Boston. He has an international reputation in the pathogenesis of
diabetic kidney disease and renal inflammation.
Dr. Brady has held many national and international leadership roles,
including Chairman of the Irish Health Research Board and Chairman of
the Universitas 21 Network of global research universities. He is also a
non-executive director of Kerry Group plc.
"I am very pleased that Dr Brady has joined the board" commented
Mr. Thomas Lynch, Chairman. "His inspirational leadership of UCD,
Irelands' largest university, during the past ten years, extensive
international experience, especially in Asia coupled with a
distinguished career as an academic clinician in Ireland and the United
States will bring invaluable experience and expertise to ICON."
This press release contains forward-looking statements. These statements
are based on management's current expectations and information currently
available, including current economic and industry conditions. These
statements are not guarantees of future performance or actual results,
and actual results, developments and business decisions may differ from
those stated in this press release. The forward-looking statements are
subject to future events, risks, uncertainties and other factors that
could cause actual results to differ materially from those projected in
the statements, including, but not limited to, the ability to enter into
new contracts, maintain client relationships, manage the opening of new
offices and offering of new services, the integration of new business
mergers and acquisitions, as well as economic and global market
conditions and other risks and uncertainties detailed from time to time
in SEC reports filed by ICON, all of which are difficult to predict and
some of which are beyond our control. For these reasons, you should not
place undue reliance on these forward-looking statements when making
investment decisions. The word "expected" and variations of such words
and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they are
made and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information, future
events or otherwise. More information about the risks and uncertainties
relating to these forward-looking statements may be found in SEC reports
filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
available on the SEC's website at http://www.sec.gov.
ICON plc is a global provider of outsourced development services
to the pharmaceutical, biotechnology and medical device industries. The
company specialises in the strategic development, management and
analysis of programs that support clinical development - from compound
selection to Phase I-IV clinical studies. With headquarters in Dublin,
Ireland, ICON currently, operates from 76 locations in 37 countries and
has approximately 10,300 employees. Further information is available at www.iconplc.com.
Source: ICON plc
All at ICON.
Chief Financial Officer
+ 353 -1-291-2000
EVP Investor Relations and Corporate Development
Source: ICON plc
News Provided by Acquire Media